Introduction to Iberdomide Hydrochloride (CC-220)
Iberdomide hydrochloride, also known as CC-220, is a promising drug candidate under development by Bristol-Myers Squibb. It is being investigated for the treatment of systemic lupus erythematosus and relapsed/refractory multiple myeloma.
Mechanism of Action
Iberdomide hydrochloride belongs to the class of Cereblon E3 Ligase Modulation Drugs (CELMoDs), which act by targeting cereblon (CRBN) and inhibiting CRBN ubiquitination. This mechanism makes it an immunomodulatory imide drug (IMiD), similar to other drugs in its class but with potentially improved efficacy and safety profiles[1].
Current Development Stage
As of the latest updates, iberdomide hydrochloride is in Phase II clinical trials for the treatment of relapsed/refractory multiple myeloma. This phase is crucial for assessing the drug's efficacy and safety in a larger patient population.
Phase Transition Success Rate (PTSR)
According to GlobalData, Phase II drugs for refractory multiple myeloma have a 35% phase transition success rate (PTSR) for progressing into Phase III. This benchmark provides a context for the challenges and opportunities that iberdomide hydrochloride faces in its development journey[1].
Clinical Trials
Several clinical trials are ongoing or planned for iberdomide hydrochloride:
- Phase 2 Study: A phase 2 study is currently underway, combining iberdomide with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma. This study aims to evaluate the safety, tolerability, and efficacy of this combination therapy[4].
Market Projections for Multiple Myeloma
The multiple myeloma market is expected to experience significant growth in the coming years.
Market Size and Growth
- United States: The multiple myeloma market size in the United States was approximately USD 14 billion in 2022 and is expected to grow at a CAGR of 4.0% to 5% during the study period (2017-2030)[2][5].
- EU-5 Countries: In the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), the market is projected to grow at a CAGR of 4.8% during the same period[5].
- Japan and China: Japan's market is expected to grow at a CAGR of 3.9%, while China's market is anticipated to grow at a CAGR of 6.2% during the study period[5].
Incident Cases and Market Outlook
- Incident Cases: The estimated total incident multiple myeloma cases in the 7MM (the United States, EU4, the United Kingdom, and Japan) were approximately 65,500 in 2022[2].
- Market Outlook: The overall multiple myeloma market is driven by increasing incidence rates, advancements in treatment options, and a growing demand for effective therapies. Emerging drugs like iberdomide hydrochloride are expected to play a significant role in this market growth[2][5].
Competitive Landscape
The multiple myeloma market is highly competitive, with several established and emerging therapies. Iberdomide hydrochloride, with its unique mechanism of action and potential for improved efficacy and safety, is positioned to compete with other IMiDs and novel therapies.
Key Market Drivers
- Unmet Medical Needs: Despite existing treatments, there remains a significant unmet need for effective therapies for relapsed/refractory multiple myeloma, providing an opportunity for new drugs like iberdomide hydrochloride[5].
- Advancements in Treatment: Continuous advancements in the understanding of multiple myeloma and the development of targeted therapies are driving the market forward.
Market Barriers
- Regulatory Hurdles: The drug must navigate through stringent regulatory approvals, which can be challenging and time-consuming.
- Competition: The presence of established therapies and other pipeline drugs poses a competitive challenge for iberdomide hydrochloride[5].
Likelihood of Approval and Phase Transition
GlobalData's report assesses the drug-specific phase transition success rate (PTSR) and likelihood of approval (LoA) scores for iberdomide hydrochloride. These scores are compared against indication benchmarks derived from 18 years of historical drug development data. The attributes of the drug, the company, and its clinical trials play a crucial role in determining these scores[1].
Key Takeaways
- Development Stage: Iberdomide hydrochloride is currently in Phase II clinical trials for relapsed/refractory multiple myeloma.
- Market Growth: The multiple myeloma market is expected to grow significantly, driven by increasing incidence rates and advancements in treatment options.
- Competitive Landscape: The market is competitive, but iberdomide hydrochloride's unique mechanism and potential benefits position it as a promising candidate.
- Regulatory and Market Challenges: The drug must overcome regulatory hurdles and compete with established and emerging therapies.
FAQs
What is iberdomide hydrochloride (CC-220)?
Iberdomide hydrochloride, or CC-220, is a drug candidate under development by Bristol-Myers Squibb for the treatment of systemic lupus erythematosus and relapsed/refractory multiple myeloma.
What is the current development stage of iberdomide hydrochloride?
As of the latest updates, iberdomide hydrochloride is in Phase II clinical trials for the treatment of relapsed/refractory multiple myeloma.
What is the mechanism of action of iberdomide hydrochloride?
Iberdomide hydrochloride acts by targeting cereblon (CRBN) and inhibiting CRBN ubiquitination, making it an immunomodulatory imide drug (IMiD).
What are the market projections for the multiple myeloma market?
The multiple myeloma market is expected to grow at a CAGR of 4.0% to 5% in the United States, 4.8% in EU-5 countries, 3.9% in Japan, and 6.2% in China during the study period (2017-2030).
What are the key drivers and barriers for iberdomide hydrochloride in the market?
Key drivers include unmet medical needs and advancements in treatment options, while key barriers include regulatory hurdles and competition from established and emerging therapies.
What is the phase transition success rate (PTSR) for Phase II drugs in multiple myeloma?
The PTSR for Phase II drugs in refractory multiple myeloma is approximately 35%.
Sources
- Pharmaceutical Technology: "Iberdomide hydrochloride by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval and Phase Transition Success Rate Model"[1].
- PR Newswire: "Multiple Myeloma Market to Observe Impressive Growth at a CAGR of 5% During the Study Period 2019-2032, Assesses DelveInsight"[2].
- Cocrystal Pharma: "Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs"[3].
- EU Clinical Trials Register: "A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma"[4].
- GlobeNewswire: "Multiple Myeloma Industry Landscape, 2030"[5].